Holen Sie sich die Stockscreener-App
1.61
1.90%
0.03
Handel nachbörslich:
1.61
Lineage Cell Therapeutics Inc Aktie (LCTX) Neueste Nachrichten
Insider Buying: Brian Culley Acquires 15,000 Shares of Lineage C - GuruFocus
Lineage Cell Therapeutics, Inc. Files Form 8-K for At-The-Market Offering – Key Company and Security Information (LCTX, NYSEAMER) 232425 - Minichart
Lineage Cell Therapeutics files prospectus supplement for up to $60 million share offering - Investing.com
Lineage Therap Expands ATM Equity Offering Capacity - TipRanks
Lineage Cell Therapeutics files prospectus supplement for up to $60M ATM equity offering - TradingView
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
US Market Wrap: Is Klotho Neurosciences Inc gaining market shareGap Down & Daily Technical Forecast Reports - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Lineage Cell Therapeutics (LCTX) Mar 2026 - Meyka
Lineage Cell Therapeutics Extends Runway Amid R&D Surge - TipRanks
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why Lineage Cell Therapeutics Inc. stock could outperform in 2026Portfolio Performance Summary & Free Verified High Yield Trade Plans - Naître et grandir
Regulatory Risks Loom for Lineage Cell Therapeutics as Legacy Pluripotent Cell Lines Face Potential Compliance Challenges - TipRanks
Can Lineage Cell Therapeutics Inc. stock resist market sell offsQuarterly Growth Report & Long Hold Capital Preservation Plans - Naître et grandir
Risk Off: Is Lineage Cell Therapeutics Inc stock overvalued or fairly pricedJuly 2025 Momentum & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Price Target Raised to $3.00 - MarketBeat
LCTX Stock Rating Maintained as Buy; Price Target Raised by D. B - GuruFocus
H.C. Wainwright reiterates Buy on Lineage Cell stock, $9 target - Investing.com South Africa
Lineage Cell Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Lineage Cell Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Lineage Cell Therapeutics (LCTX) Extends Cash Runway with Positi - GuruFocus
Lineage Cell Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Investing News Network
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides B - PharmiWeb.com
Lineage Cell (LCTX) Reports Break-Even Earnings for Q4 - Yahoo Finance
Lineage Cell Therapeutics (LCTX) Sees Revenue Surge in Q4 - GuruFocus
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Releases Quarterly Earnings Results, Beats Estimates By $0.07 EPS - MarketBeat
Lineage Cell Therapeutics posts fourth quarter and full year 2025 financial results ahead of update call - Traders Union
Lineage Cell Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
LCTX,BTX Volatility & Greeks - Finviz
Lineage Cell Therapeutics (LCTX) Q4 Earnings Preview: Key Expectations - GuruFocus
LCTX SEC FilingsLineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
A Look Ahead: Lineage Cell Therapeutics's Earnings Forecast - Benzinga
LCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Lineage Cell Therapeutics (LCTX) to Release Earnings on Monday - MarketBeat
Lineage Cell Therapeutics IncWithdrew CIRM Grant Application Filed In June 2025SEC Filing - TradingView
Is now the right time to enter Lineage Cell Therapeutics Inc2025 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
LCTX PE Ratio & Valuation, Is LCTX Overvalued - Intellectia AI
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide - PharmiWeb.com
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Yahoo Finance
Institution Moves: How does Lineage Cell Therapeutics Inc compare to its peersJuly 2025 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
CEO Moves: What are the future prospects of Lineage Cell Therapeutics IncDip Buying & Expert Curated Trade Setups - baoquankhu1.vn
Revenue Check: Is Lineage Cell Therapeutics Inc a top pick in the sectorWeekly Profit Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Will Lineage Cell Therapeutics Inc. stock keep raising dividendsMarket Performance Recap & Weekly High Conviction Trade Ideas - mfd.ru
Is Lineage Cell Therapeutics Inc. still a buy after recent gainsM&A Rumor & Reliable Entry Point Alerts - mfd.ru
LCTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Lineage Cell Therapeutics Inc. stock hit new highs in YEAR2025 Investor Takeaways & Real-Time Volume Spike Alerts - mfd.ru
Is Lineage Cell Therapeutics Inc. a top pick in the sectorJuly 2025 Fed Impact & High Return Stock Watch Alerts - mfd.ru
Will Lineage Cell Therapeutics Inc. stock maintain dividend yieldMarket Sentiment Summary & Stepwise Trade Signal Implementation - mfd.ru
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from D. Boral Capital - Defense World
D. Boral Capital Reiterates "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics (LCTX) Receives Consistent Buy Rating from D. Boral Capital | LCTX Stock News - GuruFocus
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
Progress In Research Spring 2024 - Christopher & Dana Reeve Foundation
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Investing News Network
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Benzinga
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 3.1%Here's What Happened - MarketBeat
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):